Breaking News Instant updates and real-time market news.

NVS

Novartis

$86.24

0.9 (1.05%)

, ECYT

Endocyte

$23.40

7.85 (50.48%)

16:35
10/18/18
10/18
16:35
10/18/18
16:35

Fly Intel: Wall Street's top stories for Thursday

Stocks opened in negative territory on the heels of Chinese stock markets having fallen nearly 3% overnight. The U.S. averages moved in a wide range in the early going, but were never able to gain upside momentum. The S&P was down just a few points as of 11 am ET before coming for sale and spending the rest of the session deep in negative territory. The Nasdaq has now lost ground in nine of the past ten sessions and is in the midst of one of its worst months of the year. Oil prices are lower despite the tension with Saudi Arabia and its threat to retaliate with oil to any sanctions the U.S. may impose from the death of Jamal Khashoggi. The price of crude oil settled down 1.5% at $68.65 a barrel. ECONOMIC EVENTS: In the U.S., initial jobless claims fell 5,000 to 210,000 in the week ended October 13. The Philly Fed index dipped 0.7 ticks to 22.2 in October, which was a little better than forecast. The leading economic indicators index rose 0.5% to 111.8 in September, which is a fresh record peak and a little better than forecast. Additionally, Treasury Secretary Steve Mnuchin announced that, after meeting with President Trump and Secretary of State Mike Pompeo, they have decided he will not be participating in the Future Investment Initiative summit in Saudi Arabia. COMPANY NEWS: Novartis (NVS) reported mixed Q3 results, with core EPS that narrowly topped consensus and revenue that missed the average forecast, while also backing its view of FY18 core operating income growth. Additionally, the company announced a deal to acquire Endocyte (ECYT) for $24 per share, or a total equity value of approximately $2.1B in cash. Endocyte shares rose 50% to $23.40 following the news, while Novartis shares closed 1% higher... Shares of Travelers (TRV) slid 1% despite the Dow member reporting Q3 earnings and revenue that topped estimates... Coca-Cola (KO) announced key changes in top leadership, naming Brian Smith to serve as president and COO, effective Jan. 1, 2019. John Murphy, who currently serves as president of the company's Asia Pacific group, will become executive vice president and CFO on March 16, 2019, following the retirement of Kathy Waller... Apple (AAPL) announced a Special Event that will be broadcast live from Brooklyn, New York on October 30. It is assumed that the company will be presenting a refreshed line up of iPads and Mac computers... Meanwhile, Netflix (NFLX) shares fell nearly 5% after NBC News reported that company executives have been bracing employees for a Wall Street Journal investigation that they are expecting to be similar to The New York Times' critical 2015 look into Amazon's (AMZN) corporate culture. MAJOR MOVERS: Among the noteworthy gainers was Acadia (ACHC), which rose 8% after Reuters reported that the company is in talks with private equity firms about selling itself. Also higher was Alcoa (AA), which gained 6% after reporting quarterly results. Among the notable losers was Apellis (APLS), which dropped 17% after the company voluntarily implemented a temporary pause in dosing in its Phase 3 geographic atrophy program. Also lower was Snap-On (SNA), which fell about 10% after reporting quarterly results. INDEXES: The Dow fell 327.23, or 1.27%, to 25,379.45, the Nasdaq lost 157.56, or 2.06%, to 7,485.14, and the S&P 500 declined 40.43, or 1.44%, to 2,768.78.

NVS

Novartis

$86.24

0.9 (1.05%)

ECYT

Endocyte

$23.40

7.85 (50.48%)

TRV

Travelers

$125.08

-1.39 (-1.10%)

KO

Coca-Cola

$45.64

-0.22 (-0.48%)

AAPL

Apple

$215.98

-5.22 (-2.36%)

NFLX

Netflix

$346.71

-18.24 (-5.00%)

AMZN

Amazon.com

$1,771.45

-61.36 (-3.35%)

ACHC

Acadia

$38.57

2.8 (7.83%)

AA

Alcoa

$38.85

2.14 (5.83%)

APLS

Apellis

$13.80

-2.85 (-17.12%)

SNA

Snap-On

$151.46

-16.15 (-9.64%)

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 13

    Nov

  • 03

    Mar

NVS Novartis
$86.24

0.9 (1.05%)

10/18/18
HCWC
10/18/18
NO CHANGE
Target $280
HCWC
Buy
Ligand current valuation brings attractive entry point, says H.C. Wainwright
Ligand Pharmaceuticals (LGND) partner Novartis (NVS) announced this morning Q3 Promacta revenue of $295M, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The sales missed his estimate of $318M and came close to the consensus of $295.8M. Importantly, in the first nine months of 2018, Promacta total sales were $844M, representing 37% growth for the first nine-month period in 2017, the analyst points out. He continues to be impressed with the Promacta franchise, which he notes represents a cornerstone of Ligand's royalty revenue for the long term. Pantginis believes the recent pullback in shares of Ligand presents an attractive entry point and "compelling accumulation opportunity." He reiterates a Buy rating on the name with a $280 price target.
10/18/18
WEDB
10/18/18
DOWNGRADE
WEDB
Neutral
Endocyte downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Endocyte (ECYT) to Neutral after the company agreed to be acquired by Novartis (NVS) for $24 per share. The analyst does not next another bidder to emerge.
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
ECYT Endocyte
$23.40

7.85 (50.48%)

07/16/18
WEDB
07/16/18
NO CHANGE
Target $21
WEDB
Outperform
Endocyte price target raised to $21 from $15 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Endocyte to $21 from $15 as Xofigo safety concerns should strengthen 177Lu's competitive positioning. The analyst reiterates an Outperform rating on the shares.
04/13/18
JEFF
04/13/18
INITIATION
Target $17
JEFF
Buy
Endocyte initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft starts Endocyte with a Buy rating and $17 price target. The analyst believes the company's CAR-T program is "under-the-radar" and could have broad use in oncology.
03/09/18
03/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Corcept Therapeutics (CORT) initiated with a Buy at B. Riley FBR. 2. Masimo (MASI) initiated with an Overweight at Barclays. 3. Ovid Therapeutics (OVID) initiated with an Overweight at Piper Jaffray. 4. Endocyte (ECYT) initiated with an Outperform at Wells Fargo. 5. Cloudera (CLDR) initiated with a Neutral at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TRV Travelers
$125.08

-1.39 (-1.10%)

06/06/18
KBWI
06/06/18
NO CHANGE
KBWI
Amazon unlikely to overly disrupt insurance market, says Keefe Bruyette
Amazon.com's (AMZN) possible entry into homeowners insurance is unlikely to be "overly disruptive" to the industry, Keefe Bruyette analyst Meyer Shields told investors earlier in a research note. The analyst says that in the past, the U.S has been a relatively slow adopter of online insurance offerings. Names in the property and casualty insurance space include AIG (AIG), Allstate (ALL), Chubb (CB), Hartford Financial (HIG), Progressive (PGR) and Travelers (TRV).
07/12/18
SBSH
07/12/18
NO CHANGE
Target $144
SBSH
Buy
Citi opens 'Catalyst Watch' on Travelers ahead of earnings
Citi analyst James Naklicki opened a "Catalyst Watch on Travelers and is "tactically positive" on the stock into the quarterly earnings report. The analyst favors the Property and Casualty insurance brokers over the next 12-18 months saying U.S. commercial pricing is "modestly positive and will be a tailwind for organic growth this year." He lowered his price target for Travelers to $144 from $155 and keeps a Buy rating on the name.
07/24/18
MKMP
07/24/18
NO CHANGE
Target $125
MKMP
Neutral
Travelers price target lowered to $125 from $140 at MKM Partners
MKM Partners analyst Harry Fong lowered his price target on Travelers to $125 after its Q2 earnings miss, saying the quarter was impacted by "several large commercial losses, chiefly from fire losses and an assessment from the Texas windstorm pool related to Hurricane Harvey". The analyst notes that the sell off in the stock was somewhat surprising, since the earnings miss was due to "normal insurance noise" that is typical for the industry. Fong also keeps his Neutral rating on Travelers which he attributes to 1.4-times trailing book value multiple, rather than its recent earnings proposal.
08/07/18
FBCO
08/07/18
INITIATION
Target $141
FBCO
Neutral
Travelers initiated with a Neutral at Credit Suisse
Credit Suisse analyst Michael Zaremski started Travelers (TRV) with a Neutral rating and $141 price target. For shorter-term oriented investors, the analyst recommends Travelers over peer Chubb (CB) due to having more conviction over its recent string of higher than expected non-catastrophe weather-related losses subsiding, a greater gearing to workers' comp. leading to a steady stream of reserve releases given an extremely healthy unemployment backdrop, and conviction that near-term auto margins will continue to improve given industry pricing dynamics. In the longer term, he struggles to make the case that Travelers' wheels business can produce better and less volatile results.
KO Coca-Cola
$45.64

-0.22 (-0.48%)

09/14/18
GUGG
09/14/18
INITIATION
Target $51
GUGG
Buy
Coca-Cola initiated with a Buy on above consensus growth at Guggenheim
Guggenheim analyst Laurent Grandet initiated Coca-Cola with a Buy and $51 price target and above consensus estimates saying the company is now focused on aggressively innovating across the non-alcoholic beverage space. Grandet sees growth driven by the company's global market leadership in the highly profitable carbonated soft drink segment, rapid and aggressive innovation combined with an acquisition strategy, dominance in on-premise, strength of global Coke bottling system, and an asset light operating model.
09/13/18
GUGG
09/13/18
INITIATION
GUGG
Buy
Coca-Cola initiated with a Buy at Guggenheim
09/18/18
STFL
09/18/18
NO CHANGE
Target $66
STFL
Buy
Monster Beverage likely to hike prices regardless of Red Bull, says Stifel
Stifel analyst Mark Astrachan said he still anticipates Monster Beverage will increase prices on its U.S. legacy business, which represents about two-thirds of sales, by about 4% in the fourth quarter of 2018 and raise prices on its brands acquired from Coca-Cola (KO) in the first quarter of 2019 despite industry talks that indicate Red Bull does not currently plan to follow Monster's lead. While noting that he does not view Red Bull's reported lack of current pricing intent as definitive, Astrachan said that should it not follow that he anticipates no material impact to Monster's volume or share trends based on his analysis of the last price increase by both companies in 2015. He maintains a Buy rating and $66 price target on Monster shares.
10/03/18
RBCM
10/03/18
NO CHANGE
Target $115
RBCM
Sector Perform
PepsiCo price target raised to $115 from $111 at RBC Capital
RBC Capital analyst Nik Modi raised his price target on PepsiCo (PEP) to $115 after its Q3 results, saying the accelerated from the first half 5% organic growth was better than his expected 2.4% and marked an "encouraging beat". The analyst notes however that the "spike" in growth came at a cost of a 70bps operating margin contraction and keeps his Sector Perform rating, forecasting Coca-Cola (KO) to continue outgrowing PepsiCo because of its "better execution".
AAPL Apple
$215.98

-5.22 (-2.36%)

10/18/18
WEDB
10/18/18
INITIATION
WEDB
Outperform
Apple initiated with an Outperform at Wedbush
10/15/18
GSCO
10/15/18
NO CHANGE
Target $240
GSCO
Neutral
China consumer slowdown raises risk for Apple, says Goldman Sachs
Noting multiple signs of rapidly slowing consumer demand in China, Goldman Sachs analyst Rod Hall said he sees risk to demand for Apple's products, adding that much of his view of Apple's upside potential was centered on Chinese demand for larger screen sizes. However, he also flags the offsetting positive trend of 6"+ phone conversions in both China and elsewhere. While Hall reiterates his December quarter iPhone shipments estimate of 80M and keeps a Neutral rating and $240 price target on Apple shares, he sees risk that Apple's potential to "beat and raise" in Q4 is likely reduced should weak consumer demand persist in China.
10/12/18
WEDB
10/12/18
UPGRADE
Target $6.5
WEDB
Outperform
Fitbit upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Michael Pachter upgraded Fitbit (FIT) to Outperform from Neutral, citing the company's expansion into the healthcare/MedTech vertical. In a research note to investors, Pachter says Fitbit has captured a large share of both the smartwatch and fitness tracker markets, but its watches must compete with Apple's (AAPL) offering. He thinks Fitbit has an "excellent" opportunity ahead with MedTech, particularly in collaboration with Google (GOOG, GOOGL), and believes Fitbit may begin reporting meaningful contribution from MedTech as early as 2019. Pachter also notes that shares have recently pulled back well below his $6.50 price target, providing an opportunity to get involved in the Medtech vertical at a reasonable price.
10/18/18
MSCO
10/18/18
NO CHANGE
Target $247
MSCO
Overweight
Morgan Stanley says China a near-term headwind for Apple's App Store growth
Morgan Stanley analyst Katy Huberty noted that data from Sensor Tower imply App Store net revenue recognized by Apple of $3.6B in the September quarter, which would be a quarterly high but below her forecast of $3.8B. Assuming her other estimates for Services are correct, this would imply September quarter Services revenue of $9.8B, which Huberty notes would be below her current $10.0B estimate and below the current consensus of $10.1B. She said a pause in new gaming approvals in China, coupled with fear of economic slowdown there, present a near-term headwind for App Store growth, but she sees limited downside to near-term Apple estimates and remains bullish on Services growth over the longer-term. Huberty keeps an Overweight rating and $247 price target on Apple shares.
NFLX Netflix
$346.71

-18.24 (-5.00%)

10/17/18
FBCO
10/17/18
NO CHANGE
Target $470
FBCO
Outperform
Netflix growth story back on track, says Credit Suisse
Credit Suisse analyst Douglas Mitchelson believes the Netflix subscriber growth story is back on track with 2018 net additions now estimated at 29.0M, accelerating 22% from 2017's 23.8M, and the content slate expansion potentially driving further acceleration in 2019. The analyst believes growth from Asia is kicking in, more mature markets seem to be holding in and Europe likely continues to expand. He reiterates an Outperform rating and $470 price target on the shares.
10/18/18
OPCO
10/18/18
NO CHANGE
Target $410
OPCO
Outperform
Netflix price target raised to $410 from $370 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Netflix to $410 from $370 after the company reported better than expected Q3 results and Q4 guidance. The analyst believes better Q4 International subscriber guidance bodes well for 2019 outlook and long-term global penetration. While bears will point to lower Q4 margin guidance, he thinks Netflix continues to build a bigger moat as the majority of content spend is through its internal studio, which protects the company from media consolidation and forthcoming over-the-top services. Helfstein now estimates 2025 global broadband penetration of 35%, with additional upside as 5G allows the company to create a mobile offering. He reiterates an Outperform rating on the shares.
10/18/18
ARGS
10/18/18
NO CHANGE
ARGS
Hold
Netflix valuation remains 'significantly higher' than peers, says Argus
Argus analyst Joseph Bonner kept his Hold rating on Netflix after its Q3 results, saying that while the quarter saw a beat on its streaming membership subscriber adds, it also forecast a decline in operating income with some costs slipping into the next quarter. The analyst also lowers his FY18 EPS view to $2.66 from $2.83 and FY19 EPS view to $4.20 from $4.36, noting that although the market reaction to earnings was positive, Netflix took on more debt to ramp up its original production and content licensing, which resulted in a "stunningly high cash burn rate". Bonner continues to see Netflix stock trading at "significantly higher than peers" multiples on historical and forward basis even as it attracts a host of competitors.
10/17/18
10/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Infosys (INFY) downgraded to Neutral from Buy at Goldman Sachs with analyst Sumeet Jain saying yesterday's Q2 results were in-line but at the expense of "unexpectedly" higher investments. 2. Netflix (NFLX) downgraded to Sector Weight from Overweight at KeyBanc with analyst Andy Hargreaves citing quarterly results. While the analyst maintains a favorable view of Netflix's strategic positioning, he believes improving investment efficiency or significant ancillary opportunities are needed to drive upside from current levels, and he does not anticipate either over the next year. 3. Home Depot (HD), Lowe's (LOW), KB Home (KBH), and Lennar (LEN) were downgraded to Neutral from Outperform at Credit Suisse. 4. Del Taco (TACO) downgraded to Neutral from Buy at BTIG with analyst Peter Saleh citing the "combination of negative traffic and rising food and labor inflation" weighing on its prospects for the coming year, adding that while he is optimistic on its promotions and delivery potential, he is also worried about customers being discouraged by the company's higher pricing. 5. Scorpio Bulkers (SALT) downgraded to Neutral from Overweight at JPMorgan with analyst Noah Parquette citing the company's related party transactions and recent investment in Scorpio Tankers (STNG) for the downgrade. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMZN Amazon.com
$1,771.45

-61.36 (-3.35%)

10/17/18
LOOP
10/17/18
NO CHANGE
Target $2200
LOOP
Buy
Amazon Q3 EPS view raised at Loop Capital
Loop Capital analyst Anthony Chukumba kept his Buy rating and $2,200 price target on Amazon.com ahead of its Q3 earnings next Thursday but raised his EPS view to $3.26 from $2.78, reflecting "higher North America profitability expectations, including continued advertising growth and fixed expense leverage". The analyst also notes that his forecast reflects anticipated 32.3% net sales growth, driven by 40.0% and 37.5% growth in AWS and North America and a 220 bps y/y operating margin increase. Chukumba adds that Amazon's better than expected profitability, "particularly in International", would make him more bullish on the stock.
10/18/18
DADA
10/18/18
NO CHANGE
Target $2450
DADA
Buy
Impact from Amazon's minimum wage hike to come into focus, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $2,450 price target on Amazon.com ahead of its Q3 results next Thursday, saying the company's "profit engines" - advertising, AWS, and 3rd party sales - will be in focus. The analyst also expects investors to pay particularly close attention to Amazon's Q4 outlook after the management's decision to boost its minimum wage to $15 per hour effective November 1st, adding that he would not be surprised if payroll expenses were forecast to rise by mid-single digits.
10/17/18
LOOP
10/17/18
NO CHANGE
Target $385
LOOP
Hold
Netflix price target raised to $385 from $365 at Loop Capital
Loop Capital analyst Alan Gould raised his price target on Netflix (NFLX) to $385 from $365 after its reported strong subscription adds in Q3 and expectations of more adds in Q4. The analyst also points to the management's FY19 operating margin target of 13% - up from 10%-11% target for FY18 - and expectations of "peak" negative free cash flows in the next two years. Gould also keeps his Hold rating on Netflix given the ongoing risks around competition from Amazon (AMZN) and other content providers along with a strong USD weighing on international sales.
10/17/18
BARD
10/17/18
NO CHANGE
Target $2100
BARD
Outperform
Baird recommends adding to Amazon positions on any earnings volatility
Baird analyst Colin Sebastian expects solid Q3 results from Amazon and recommends the shares on the recent weakness and to add to positions on any earnings related volatility. The analyst said it remains a top pick given momentum across high margin business segments. He said there is potential for noise around Q4 profit margins due to higher labor costs and the potential for USPS last mile rate increases. Sebastian reiterated his Outperform rating and $2,100 price target on Amazon shares.
ACHC Acadia
$38.57

2.8 (7.83%)

10/18/18
MZHO
10/18/18
NO CHANGE
Target $37
MZHO
Neutral
Mizuho sees maximum Acadia leveraged buyout price at $48 per share
Mizuho analyst Ann Hynes reiterates this morning that her model suggests Acadia Healthcare's (ACHC) maximum leveraged buyout take-out price is $48.00 per share given its current debt levels. The stock in premarket trading is up 8%, or $3.32, to $39.00 after Reuters reported that the company is in talks with private equity firms about selling itself after attracting buyout interest. KKR (KKR) and TPG Global are among the private equity firms that have approached Acadia, according to Reuters. Hynes keeps a Neutral rating on Acadia shares with a $37 price target.
10/18/18
LEER
10/18/18
NO CHANGE
LEER
Acadia may receive 11-12 times multiple in private equity takeout, says Leerink
Following reports saying KKR (KKR) and TPG Global are reportedly in talks with Acadia (ACHC) on a take-private deal, Leerink analyst Ana Gupte notes that private equity has always been interested in the company given its addiction treatment centers acquired through CRC Health and outpatient focus on eating disorders and substance abuse, though the multiples at which a takeout would be acceptable to Acadia's management were unclear. The analyst expects the recent news flow on understaffing and quality of service delivery at Acadia in the short news report may be driving more willingness to entertain such a take private of the company. Gupte believes a 11-12 times multiple is likely and represents upside of about 35%-55% on the current $35 per share trading price.
10/18/18
BARD
10/18/18
NO CHANGE
Target $42
BARD
Neutral
Baird puts Acadia buyout price at $40-$45, says not chasing shares
Baird analyst Matthew Gillmor is not surprised by the reports that Acadia Healthcare is in talks to sell itself to private equity firms given considering management's history and the complexities with the U.K. business. His analysis suggests a leveraged buyout in the $40 to $45 per share range "could make sense" for a private equity bidder, with "perhaps some optionality" from separating the U.S. and U.K. operations over time. With the stock trading "just" 10% below his leveraged buyout takeout valuation, Gillmor says he's not inclined to chase the stock on today's rally. He keeps a Neutral rating on Acadia with a $42 price target. The stock in morning trading is up 9%, or $3.23, to $39.00.
10/18/18
FBCO
10/18/18
NO CHANGE
FBCO
Acadia could be worth $43 per share in takeout, says Credit Suisse
In his leveraged buyout scenario, Credit Suisse analyst A.J. Rice says Acadia could be worth $43 per share. The analyst assumes top-line growth in the 6%-7% range and that margins grow from 21% in 2018 to 22.7% by 2023. Further, Rice believes the buyer could split the U.S. and U.K. businesses, which would likely be immediately accretive to the valuation of the U.S. business and give optionality to bringing on a partner on the U.K. side. The analyst notes that leveraged buyouts are not new to Acadia management, but adds that he sees no obvious strategic buyer here.
AA Alcoa
$38.85

2.14 (5.83%)

10/09/18
MSCO
10/09/18
NO CHANGE
Target $57
MSCO
Overweight
Alcoa has 10% potential upside if tariffs replaced, says Morgan Stanley
Morgan Stanley analyst Piyush Sood noted that U.S. steel and aluminum tariffs were left in place under the USMCA agreement, but President Trump said they were only being left in place "until such time as we can do something that would be different, like quotas." Replacing U.S. import tariffs on Canadian aluminum with duty-free quotas could add about $150M to Alcoa's annual EBITDA, calculated Sood, who said that equates to about a 10% potential upside in the stock "that the market has so far ignored." The analyst, who sees Alcoa's Q3 results coming in ahead of expectations, keeps an Overweight rating and $57 price target on the shares.
10/18/18
JPMS
10/18/18
NO CHANGE
Target $79
JPMS
Overweight
Alcoa price target raised to $79 from $75 at JPMorgan
JPMorgan analyst Michael Gambardella raised his price target for Alcoa to $79 saying the company last night reported a "solid Q3 beat" and continues to operate well in "turbulent" alumina and aluminum markets. With a $200M buyback program announced, the analyst thinks Alcoa will use its cash going forward for repurchases and to continue to reduce its debt and pension obligations. He believes the stock price is "discounting too steep of a drop in alumina and aluminum prices." Gambardella keeps an Overweight rating on Alcoa.
10/18/18
BMOC
10/18/18
NO CHANGE
Target $75
BMOC
Outperform
Alcoa remains 'meaningfully undervalued', says BMO Capital
BMO Capital analyst David Gagliano kept his Outperform rating and $75 price target on Alcoa after its Q3 earnings beat and additional $200M stock buyback, maintaining his view that the shares are "meaningfully undervalued" even under the "risk-off" environment assumptions. The analyst notes that the company's earnings beat was driven by its aluminum segment profitability thanks to the strong contributions from energy and flat-rolled products. Gagliano also contends that there is a disconnect between Alcoa valuation multiples typically seen at the peak of the underlying pricing cycle and its compressed marginal cost prices.
10/18/18
FBCO
10/18/18
NO CHANGE
Target $58
FBCO
Outperform
Alcoa too cheap to ignore, says Credit Suisse
Credit Suisse analyst Curt Woodworth believes Alcoa is "significantly undervalued" and thinks the strong operating performance in Q3 and continued tightness in alumina set the stage for meaningful earnings revisions across the Street. The analyst reiterates an Outperform rating and $58 price target on the shares.
APLS Apellis
$13.80

-2.85 (-17.12%)

07/10/18
COWN
07/10/18
INITIATION
Target $40
COWN
Outperform
Apellis initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated Apellis with an Outperform and $40 price target.
07/30/18
RILY
07/30/18
UPGRADE
Target $27
RILY
Buy
Apellis upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar upgraded Apellis Pharmaceuticals to Buy with unchanged price target of $27. The recent pullback in the shares ignores the opportunity of APL-2 in geographic atrophy, Kumar tells investors in a research note. He cites valuation for the upgrade to Buy.
10/18/18
CANT
10/18/18
NO CHANGE
CANT
Apellis dosing pause may not impact program timelines, says Cantor Fitzgerald
Apellis Pharmaceuticals last night reported that it initiated a temporary pause in dosing for its Phase 3 geographic atrophy program due to the occurrence of non-infectious inflammation associated potentially with a single lot of APL-2 drug, Cantor Fitzgerald analyst Elemer Piros tells investors in a research note. The analyst says that while he awaits additional investigation to better understand the associated factors leading to the single drug lot, he believes these activities may end up having no impact on Apellis' GA program's timelines to commercialization. That being said, the analyst expects manufacturing safeguards and processes to become a focus for investors. In a research note titled "Road Bump on Single Drug Lot, but Potential Remains to Stay on Track," Piros keeps an Overweight rating on Apellis with a $53 price target.
07/10/18
COWN
07/10/18
INITIATION
Target $40
COWN
Outperform
Apellis initiated with an Outperform on APL-2 potential at Cowen
Cowen analyst Phil Nadeau initiated Apellis Pharmaceuticals with a Outperform and $40 price target saying lead candidate APL-2 has produced solid clinical data in geographic atrophy and paroxysmal nocturnal hemoglobinuria and believes peak worldwide revenue potential could be +$1B.
SNA Snap-On
$151.46

-16.15 (-9.64%)

07/24/18
NRCS
07/24/18
DOWNGRADE
NRCS
Neutral
Snap-On downgraded to Neutral on share strength at Northcoast
Northcoast analyst Tom Hayes downgraded Snap-On to Neutral from Buy citing recent price appreciation.
07/17/18
LBOW
07/17/18
NO CHANGE
LBOW
Neutral
Snap-On checks point to below-consensus Q2 for U.S. franchisees, says Longbow
Longbow analyst David Macgregor said his survey of U.S. franchisees of Snap-On points to a below-consensus quarter, as they report flat to 2% declines across core tools and that financial services originations are down 4% to 6%. He has a Neutral rating on Snap-On shares.
06/26/18
BARD
06/26/18
NO CHANGE
Target $210
BARD
Outperform
Snap-On risk/reward favorable ahead of upcoming inflection, says Baird
Baird analyst David Leiker said the risk/reward for Snap-On is favorable ahead of a second half inflection of organic growth for the company's Tools Group. He sees a re-acceleration in organic growth at a time when Industrials are slowing, which can help narrow Snap-On's discount to the group and push the stock back above $200. Leiker reiterated his Outperform rating and extended its Fresh Pick designation while maintaining his $210 price target on Snap-On shares.
04/20/18
BARD
04/20/18
NO CHANGE
Target $210
BARD
Outperform
Snap-On remains battleground stock, but moving in right direction, says Baird
Baird analyst David Leiker said Snap-On remains a battleground stock, but he believes the company is moving in the right direction following its Q1 results. He believes the shares will outperform over the next 12 months as growth and margin metrics were better than expected and he sees the Tools Group inflecting to positive growth. Leiker reiterated his Outperform rating and raised his price target to $210 from $204 on Snap-On shares.

TODAY'S FREE FLY STORIES

AAPL

Apple

$193.42

2 (1.04%)

, PCG

PG&E

$24.39

6.62 (37.25%)

19:29
11/18/18
11/18
19:29
11/18/18
19:29
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$193.42

2 (1.04%)

PCG

PG&E

$24.39

6.62 (37.25%)

CBS

CBS

$57.49

0.23 (0.40%)

VIA

Viacom

$37.05

0.96 (2.66%)

VIAB

Viacom

$33.00

1.13 (3.55%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

TGT

Target

$79.67

-1.09 (-1.35%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TIF

Tiffany

$106.48

0.52 (0.49%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TJX

TJX

$51.47

-0.98 (-1.87%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

LB

L Brands

$35.28

-0.41 (-1.15%)

T

AT&T

$30.30

0.18 (0.60%)

BP

BP

$40.85

-0.3 (-0.73%)

CVX

Chevron

$119.14

2.18 (1.86%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

APC

Anadarko

$56.39

0.9 (1.62%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

AMGN

Amgen

$194.23

1.83 (0.95%)

THS

TreeHouse

$51.92

0.72 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 26

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 18

    Jan

  • 22

    Jan

  • 03

    Mar

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

, BX

Blackstone

$32.48

-0.02 (-0.06%)

18:50
11/18/18
11/18
18:50
11/18/18
18:50
Periodicals
Zayo said to get interest from Blackstone-Stonepeak Group, Bloomberg reports »

Zayo (ZAYO) has attracted…

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

BX

Blackstone

$32.48

-0.02 (-0.06%)

KKR

KKR

$21.83

-0.46 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 03

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:08
11/18/18
11/18
18:08
11/18/18
18:08
Periodicals
PG&E reports another outage on morning when California started, Reuters says »

PG&E, facing investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KL

Kirkland Lake Gold

$18.97

0.28 (1.50%)

18:04
11/18/18
11/18
18:04
11/18/18
18:04
Hot Stocks
Kirkland Lake Gold appoints David Soares as CFO, Eric Kallio as senior VP »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPD

Expeditors

$73.67

0.14 (0.19%)

17:19
11/18/18
11/18
17:19
11/18/18
17:19
Conference/Events
Expeditors management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CBS

CBS

$57.49

0.23 (0.40%)

, VIAB

Viacom

$33.00

1.13 (3.55%)

16:54
11/18/18
11/18
16:54
11/18/18
16:54
Periodicals
CBS, Viacom merger could be a few months away, NY Post reports »

After CBS (CBS) CEO Les…

CBS

CBS

$57.49

0.23 (0.40%)

VIAB

Viacom

$33.00

1.13 (3.55%)

VIA

Viacom

$37.05

0.96 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 04

    Dec

AIMT

Aimmune

$29.61

0.05 (0.17%)

16:51
11/18/18
11/18
16:51
11/18/18
16:51
Hot Stocks
PALISADE trial of Aimmune's AR101 published in New England Journal of Medicine »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 12

    Dec

T

AT&T

$30.30

0.18 (0.60%)

, CMCSA

Comcast

$38.60

0.11 (0.29%)

16:31
11/18/18
11/18
16:31
11/18/18
16:31
Hot Stocks
Box Office Battle: 'Fantastic Beasts 2' wins weekend with $62M »

AT&T (T) subsidiary…

T

AT&T

$30.30

0.18 (0.60%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$50.80

-0.81 (-1.57%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

LGF.A

Lionsgate

$20.88

0.365 (1.78%)

DIS

Disney

$116.20

-0.9 (-0.77%)

VIAB

Viacom

$33.00

1.13 (3.55%)

VIA

Viacom

$37.05

0.96 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

15:45
11/18/18
11/18
15:45
11/18/18
15:45
Periodicals
Volkswagen CEO says Waymo has 1/2-year head start, Reuters reports »

Volkwagen (VLKAY) is up…

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

GOOGL

Alphabet Class A

$1,069.13

-2.09 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

15:21
11/18/18
11/18
15:21
11/18/18
15:21
Hot Stocks
AT&T, Fox Networks renew multi-year deal across distribution platforms »

AT&T (T) and Fox…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

AAPL

Apple

$193.42

2 (1.04%)

13:35
11/18/18
11/18
13:35
11/18/18
13:35
Periodicals
Apple CEO views new regulations as 'inevitable,' Axios reports »

Apple CEO Tim Cook says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, RIO

Rio Tinto

$50.94

0.89 (1.78%)

13:05
11/18/18
11/18
13:05
11/18/18
13:05
Periodicals
Nespresso, Rio Tinto joining forces to make coffee pods greener, Reuters says »

Nespresso, part of food…

NSRGY

Nestle

$0.00

(0.00%)

RIO

Rio Tinto

$50.94

0.89 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$1.11

-0.095 (-7.92%)

12:54
11/18/18
11/18
12:54
11/18/18
12:54
Hot Stocks
Sonoma Pharmaceuticals announces pricing of public offering of units »

Sonoma Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 04

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/18/18
11/18
04:55
11/18/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.